Clinical Studies Search

Protocol Summary


Protocol No.
PSCI-16-135
Prinicipal Investigator
McGregor, Lisa
Phase
Phase III
Age Group
Both
Scope
National
Secondary Protocol No.
AAML1531
Title
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Objective
Primary Aims
To determine the 2-year event-free-survival (EFS) for children with standard risk DS AML (MRD-negative after one cycle of induction therapy) after elimination of HD Ara-C from the treatment regimen.
To determine the 2-year EFS for children with high risk DS AML (MRD-positive after one cycle of induction therapy) after intensification of treatment equivalent to that used for high risk AML in children without DS.
Applicable Disease Sites
Myeloid and Monocytic Leukemia
Status
Open
Participating Institutions
Hershey Medical Center